Best of ASCO - 2014 Annual Meeting

 

Welcome

Gastrointestinal Stromal Tumors (GIST)

Sarcoma

2018 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
A novel correlation between KIT promoter DNA methylation and prognostic of gastrointestinal stromal tumors.

Haibo Qiu

e23514

A phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of PLX9486 alone and in combination (combo) with the KIT inhibitors pexidartinib (pexi) or sunitinib (su) in patients (Pts) with advanced solid tumors and gastrointestinal stromal tumor (GIST).

Andrew J. Wagner

11509

A retrospective natural history study of patients (pts) with PDGFRα D842V mutant advanced gastrointestinal stromal tumor (GIST) previously treated with a tyrosine kinase inhibitor (TKI).

Margaret von Mehren

11533

Effect of sunitinib in a patient with primary imatinib-resistant gastrointestinal stromal tumor.

Zhigang Xue

e23516

Efficacy analysis of adjuvant therapy with imatinib for gastric intermediate-risk gastrointestinal stromal tumor.

Peng Zhang

e23510

Ethnic differences in hematologic toxicity from imatinib in patients with gastrointestinal stromal cell tumor (GIST).

Sneha Purvey

e23513

Immune microenvironment profiling of gastrointestinal stromal tumors (GIST).

Maria A. Pantaleo

11534

Impact of proton pump inhibitors (PPIs) on sunitinib (SU) pharmacokinetics (PK) and activity in GIST patients (pts).

Olivier Mir

11538

Interrogating the sarcoma immune microenvironment (iME) using multiplex immunohistochemistry (mIHC).

Andrew Silverman

11536

LMTK3 to regulate the translation of oncogenic KIT in GIST regardless of imatinib sensitivity.

Lillian Rose Klug

11535

Mutation profile of drug resistant gastrointestinal stromal tumor (GIST) patients (pts) enrolled in the phase 1 study of DCC-2618.

Suzanne George

11511

Overall survival in advanced GIST over time and correlation with access to post-imatinib tyrosine kinase inhibitors: Results from the Life Raft Group Registry.

Michael C. Heinrich

e23511

Paediatric, adolescent, wild type, syndromic gastrointestinal stromal tumours (PAWS-GIST): Report from United Kingdom PAWS-GIST clinic.

Venkata Ramesh Bulusu

e23519

Phase Ib study of rapid alternation of sunitinib (SU) and regorafenib (RE) in patients (pts) with advanced gastrointestinal stromal tumor (GIST).

Cesar Serrano

11510

Phase II trial of continuous dosing of regorafenib in patients with metastatic or recurrent gastrointestinal stromal tumors (GISTs) after failure of imatinib and sunitinib.

Yoon-Koo Kang

11537

Retrospective study of complete remission imatinib-free metastatic gastro-intestinal stromal tumors (GIST).

Elise Nassif

e23512

Role of resection following focal progression with standard doses of imatinib in patients with advanced gastrointestinal stromal tumor: Results of propensity score analyses.

Hyungwoo Cho

11532

The prognostic value of blood neutrophil-to-lymphocyte ratio (NLR) factor in advanced gastrointestinal stromal tumors (GIST) treated with sunitinib after imatinib failure.

Piotr Rutkowski

11531

The study of clinicopathologic correlation with the expression level of 5-hydroxymethylcytosine in GIST.

Ching-Yao Yang

e23520

To compare the efficacy of sunitinib and imatinib following cytoreductive resection in GIST patients with progression on imatinib: A multi-center controlled study.

Xinhua Zhang

11530

Utility of circulating tumor DNA (ctDNA) in the management of patients with gastrointestinal stromal tumor (GIST): Analysis of 152 patients.

Junaid Arshad

11539

Validation of the new UICC classification (8th ed.) for the staging of GIST in the TKI era.

Johanna Falkenhorst

e23517